© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Prulifloxacin belongs to the fluoroquinolone class of antibacterial agents. Developed as a synthetic compound, it acts as a prodrug for ulifloxacin, which takes effect after metabolic activation in the body. Its function connects strongly to its molecular design, targeting DNA gyrase and topoisomerase IV, essential bacterial enzymes. This unique activity gives prulifloxacin value in fighting infections such as respiratory tract, urinary tract, and certain skin infections, offering a broad spectrum that covers a wide variety of pathogenic organisms.
The chemical structure of prulifloxacin brings together a quinoline core with strategic substitutions, increasing its antibacterial power and stability. Its molecular formula is C18H19F2N3O6S, and its molar mass reaches around 443.4 grams per mole. This solid compound appears as a pale yellow powder or crystalline solid, with a melting point commonly set around 220°C to 225°C—defining its thermal stability and ease of purification during manufacturing and formulation.
Prulifloxacin offers standard solid forms like powders, flakes, or sometimes tiny pearls or granules, depending on the synthesis and subsequent handling process. Its density lies close to 1.6 grams per cubic centimeter, providing insight for storage and transport. Manufacturers tend to value these physical forms for their ease of weighing, dissolution in solution preparation, and straightforward blending during formulation of tablets and capsules. The raw material purity level ought to reach at least 99% for pharmaceutical applications, and the typical raw material batch receives precise identification through a lot number, date of production, and HS Code 2941.90 for proper customs and trade classification.
Prulifloxacin possesses both stability and mild reactivity under standard room temperature and atmospheric pressure. Moisture can degrade the compound, so it stays inside airtight, light-resistant containers, far from extreme humidity. Its solubility stands low in water yet increases in organic solvents, which directs how labs and manufacturers dissolve and formulate the substance for finished products. Researchers and chemical handlers recognize prulifloxacin as a substance demanding care; inhaling dust or accidental skin contact can provoke allergic or toxic responses in sensitive individuals. Appropriate chemical-resistant gloves, safety goggles, and dust masks matter in reducing risk. Chronic inhalation or accidental ingestion brings concern over harmful effects, including potential impacts on liver and kidney health, behavioral disturbances, and allergic skin reactions.
In my experience with chemical storage, density and material phase (either powder or crystal) make handling predictable. Prulifloxacin does not show volatility, so airborne contamination remains rare in a well-kept facility. Its raw material state—stable and non-volatile—limits accidental inhalation risk but increases the chance of skin or mucous membrane contact if unsealed in windy, unsupervised places. Prulifloxacin must stay far away from oxidizing and reducing agents, as those mixtures could lead to product instability or degradation. Material safety data sheet (MSDS) documentation lays out essential guidelines, including first aid in case of exposure and proper disposal methods for expired or contaminated batches.
The molecular formula C18H19F2N3O6S reflects a high degree of fluorination, which provides resilience against bacterial resistance. The inclusion of a sulfur atom in a side chain sometimes makes the molecule more vulnerable to oxidative environments, so sealed glass or high-grade plastic containers work best for storage. Liquid solutions of prulifloxacin may appear in research but less often in commercial pharmacy, where solid-state purity and shelf stability take priority. Laboratories achieving solution form use acidified methanol or other compatible organic solvents, with volumetric accuracy critical for determining working concentrations in any analytical, synthetic, or pharmacological process.
Sourcing prulifloxacin in the global market comes with regulatory checks, not only on purity but also on production methods, residual solvents, and environmental safety. Pharmaceutical suppliers must provide documentation for every batch, including testing for heavy metals, residual solvents, and known organic contaminants, all of which may affect both drug safety and regulatory approval. Each batch leverages the HS Code for international logistics but depends on proper customs declaration, certification, and validation during transit and receipt. Prulifloxacin remains categorized as hazardous for unskilled handling, demanding all handlers complete chemical safety training and keep facilities stocked with spill kits and first-aid support in case of accidents.
One persistent challenge in prulifloxacin production involves balancing high purity with low environmental impact. The synthesis pathway often leaves residual fluorinated by-products, and process improvements steer toward green chemistry—minimizing waste, reducing solvent use, and recycling reagents where possible. Achieving low residual solvent content in the final product not only enhances drug safety but also aligns with international pharmacopoeia standards. More investment in advanced filtration, high-performance liquid chromatography, and automation reduces the room for human error and increases quality yield. In the handling and storage space, expanding worker training and investing in updated ventilation and chemical monitoring systems lowers risks for operators and the environment. Openly publishing product test results and safety records also deepens trust between suppliers, authorities, and end users—protecting both personal safety and community well-being.
Getting to know prulifloxacin, from molecule to finished product, means tracking every step—from raw material sourcing, through manufacturing, to final handling and safety procedures. Its unique chemical features, pharmaceutical applications, and challenges in handling, storage, and disposal reveal not only the scientific but also the human dimension in modern pharmaceuticals. Tackling the risks, maintaining high purity, and embracing safe, transparent manufacturing serve not only the end users but also the workers and communities these processes touch.
